Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flodicitinib
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flodicitinib (DWP212525) is a small molecule inhibitor targeting Janus kinase 3 (JAK3) and members of the TEC family of kinases, specifically Bruton's tyrosine kinase (BTK) and Interleukin-2-inducible T-cell kinase (ITK). Developed by Daewoong Pharmaceutical, it is designed to treat various autoimmune diseases by simultaneously inhibiting multiple signaling pathways involved in B-cell and T-cell activation. The drug is currently in Phase 1 clinical development, with a primary focus on indications such as pemphigus vulgaris. By targeting both JAK and TEC family kinases, flodicitinib aims to provide a more comprehensive suppression of the immune pathways involved in B-cell and T-cell mediated inflammatory responses.
- Other names
- flodicitinibDWP212525DWP-212525DWP 212525
02
Targets
BTK (Bruton tyrosine kinase)EGFR (Epidermal growth factor receptor)ITK (Interleukin 2-inducible T-cell kinase)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on flodicitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flodicitinib.